H1B Visa Policy Changes Drive Pharmaceutical R&D and AI Operations to Indian Global Capability Centers
AI-Generated Summary
Recent increases in H1B visa fees and tightening regulations are prompting US firms to re-evaluate staffing strategies, potentially accelerating the shift of high-value work to Global Capability Centers (GCCs) in India. Industry experts anticipate a significant transfer of functions, including pharmaceutical drug discovery and AI development, to these in-house hubs, leveraging India's skilled workforce. This move is seen as a strategic response to policy changes, maintaining critical operations in-house while mitigating rising costs and talent gaps in the US.
In a nutshell
This development underscores how geopolitical regulatory shifts can profoundly influence global R&D and operational strategies within the pharmaceutical and biotech sectors, highlighting the increasing importance of distributed innovation models.
Source: NDTV Profit
